title: Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery.
abstract: OBJECTIVE
  The authors studied the effect of a direct acting antithrombin agent, desulfatohirudin variant 1 (Revasc, Ciba-Geigy, Ltd., Basel, Switzerland), on postoperative fibrin formation after cataract surgery in rabbits.
  
  
  METHODS
  Phacoemulsification was performed in a masked fashion on 28 eyes of 28 New Zealand white rabbits. Ten control group eyes had lactated Ringer's solution in the infusion and an intracameral injection (approximately 1.5 ml) at the end of the case. Ten group 1 eyes received hirudin 100 micrograms/ml in the infusion and intracameral injection. Eight group 2 eyes had 100 micrograms/ml hirudin in the intracameral injection only. Using slit-lamp examination, all eyes were graded for the amount of fibrin and intraocular hemorrhage in a masked fashion on postoperative day 1.
  
  
  RESULTS
  Comparison of the mean postoperative fibrin grade (0-4) in group 1 (mean = 0.3), group 2 (mean = 0.25) and the control group (mean = 3.4) revealed a statistically significant difference between hirudin-treated and control eyes (P = 0.0002 for group 1, P = 0.0005 for group 2). No intraocular hemorrhage was noted in any group.
  
  
  CONCLUSIONS
  Recombinant hirudin significantly decreases postoperative fibrin formation in a rabbit cataract extraction model. Intracameral injection of hirudin alone appears to be at least as effective as infusion of hirudin throughout the case. With further study, this agent has potential for use in cataract surgery on patients known to be at high risk for postoperative fibrin formation.
authors.affiliation: Duke University Eye Center, Durham, NC, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Mittra
authors.forename: S
authors.initials: S
authors.lastname: Dev
authors.forename: M A
authors.initials: MA
authors.lastname: Nasir
authors.forename: C A
authors.initials: CA
authors.lastname: Toth
mesh_terms: D000818:Animals; D000991:Antithrombins / Q000494:pharmacology*; D005337:Fibrin / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006629:Hirudins / Q000494:pharmacology*; D006801:Humans; D007267:Injections; D018918:Phacoemulsification / Q000009:adverse effects*; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D011817:Rabbits; D011994:Recombinant Proteins; D015912:Thrombolytic Therapy
chemical_list: D000991:Antithrombins; D005343:Fibrinolytic Agents; D006629:Hirudins; D011994:Recombinant Proteins; D005337:Fibrin